After primary tumor treatment, 30% of patients with malignant melanoma develop metastatic disease, usually associated with a poor prognosis. Effective chemotherapeutic regimens for metastatic melanoma are not currently available. Surgical treatment of pulmonary metastases remains controversial because of the dismal survival rates reported in several studies. However, for patients with good performance status, long disease-free interval, limited metastatic disease, and less aggressive tumor biology, it remains an option. The authors have analyzed their experience in 26 patients operated on between 2000 and 2008 alongside a review of the large series in the literature
Pulmonary metastasectomy for melanoma / Oliaro, Alberto; Filosso, Pier Luigi; Bruna, Mc; Mossetti, C; Ruffini, Enrico. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - 5 Suppl 2:(2010), pp. 187-191. [10.1097/JTO.0b013e3181dcf96d]
Pulmonary metastasectomy for melanoma
FILOSSO, Pier Luigi;
2010
Abstract
After primary tumor treatment, 30% of patients with malignant melanoma develop metastatic disease, usually associated with a poor prognosis. Effective chemotherapeutic regimens for metastatic melanoma are not currently available. Surgical treatment of pulmonary metastases remains controversial because of the dismal survival rates reported in several studies. However, for patients with good performance status, long disease-free interval, limited metastatic disease, and less aggressive tumor biology, it remains an option. The authors have analyzed their experience in 26 patients operated on between 2000 and 2008 alongside a review of the large series in the literatureFile | Dimensione | Formato | |
---|---|---|---|
523867 articolo pdf oliaro.pdf
Accesso riservato
Dimensione
689.38 kB
Formato
Adobe PDF
|
689.38 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris